Stryker Corporation

New York Stock Exchange
Back to all articles
Slightly Bullish +25

Andra AP fonden Increases Holdings in Stryker Corporation $SYK

📈 Andra AP fonden increased its Stryker holdings by 30.2% in Q1, adding 15,095 shares for a total value of $21.4 million.

🏦 Multiple other institutions including Godfrey Financial and Sankala Group established new stakes valued between $26,000 and $28,000 each.

💰 Institutional ownership stands at 77.09% while insiders own 4.60% of the company's stock.

📉 Stryker reported Q1 EPS of $2.60, missing analyst estimates of $2.98 by $0.38.

💵 Revenue for the quarter was $6.02 billion, slightly below the consensus estimate of $6.34 billion.

📈 Revenue grew 2.6% year-over-year to $6.02 billion despite the earnings miss.

🎯 The company set FY 2026 EPS guidance between $14.90 and $15.10.

💸 Insiders sold a total of 323,264 shares valued at over $100 million in the last three months.

📉 VP Robert S. Fletcher sold 4,544 shares under a pre-arranged Rule 10b5-1 trading plan.

📉 Director Ronda E. Stryker sold 310,000 shares worth $96.8 million in a single transaction.

💰 The company declared a quarterly dividend of $0.88 per share payable on July 31st.

📉 Wells Fargo reduced its price target from $456 to $418 while maintaining an 'overweight' rating.

📉 Barclays lowered its price objective from $469 to $394 but kept an 'overweight' rating.

📈 BMO Capital Markets initiated coverage with an 'outperform' rating and a $369 price target.

🏆 The stock holds a consensus 'Moderate Buy' rating with an average analyst price target of $392.52.

Bullish Signals
  • Andra AP fonden increased its stake by 30.2% in Q1, signaling strong institutional confidence in the company's long-term prospects.
  • Several other large investors including Godfrey Financial, Sankala Group, and DJE Kapital established new positions or added to existing stakes.
  • Revenue grew 2.6% year-over-year to $6.02 billion, demonstrating continued top-line growth despite a quarterly earnings miss.
  • The company has set robust full-year 2026 guidance of $14.90-$15.10 EPS, with analysts anticipating $14.99 EPS for the current year.
  • Stryker maintains a healthy dividend yield of 1.1% with a payout ratio of 40.74%, providing income to shareholders.
  • Institutional ownership remains high at 77.09%, indicating broad market interest and stability in the stock.
Risk Factors
  • Stryker missed quarterly earnings estimates by $0.38 per share, reporting $2.60 EPS against a consensus of $2.98.
  • Revenue of $6.02 billion fell short of analyst expectations of $6.34 billion for the quarter.
  • Wells Fargo reduced its price target from $456 to $418, citing concerns that may impact valuation multiples.
  • Barclays lowered its price objective from $469 to $394, reflecting a more cautious near-term outlook.
  • Significant insider selling occurred in the last three months, with insiders offloading over $100 million worth of shares.
Full Analysis
Andra AP fonden significantly increased its position in Stryker Corporation (NYSE:SYK) by 30.2% in the first quarter, purchasing an additional 15,095 shares to hold a total of 65,055 shares valued at $21.4 million. This move aligns with several other institutional investors who recently established new stakes or added to their positions in the medical technology company during the third and fourth quarters. Despite the institutional buying activity, Stryker reported mixed financial results for the quarter ended April 30th. The company posted earnings per share of $2.60, missing analyst consensus estimates of $2.98 by $0.38, while revenue reached $6.02 billion against an expected $6.34 billion. However, the company maintained a positive trajectory with revenue growing 2.6% year-over-year and setting full-year 2026 guidance between $14.90 and $15.10 per share. Insider trading activity saw notable sales from executive VP Robert S. Fletcher and Director Ronda E. Stryker, with combined insider sales totaling over $100 million in the last three months. Analyst sentiment remains cautiously optimistic with a consensus 'Moderate Buy' rating and an average price target of $392.52, though recent downgrades from Wells Fargo and Barclays have lowered specific price targets to the high $300s.